Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.
Cancer Discov. 2021 Dec 1;11(12):2987-2997. doi: 10.1158/2159-8290.CD-21-0901.
Our knowledge of how clonal hematopoiesis relates to diverse health conditions has grown vastly over the past years, touching upon many specialties beyond cancer medicine. Given that clonal hematopoiesis can act as a precursor to overt disease in many settings, the promise of early intervention has garnered much attention. In this review, we discuss the state of clonal hematopoiesis research and outline the challenges in developing clinical trials of early interventions. We anticipate that incidental findings of clonal hematopoiesis will become more common in the near future, but evidence-based efforts of how to manage these findings is currently lacking.
Our knowledge regarding the relevance of clonal hematopoiesis has increased drastically over the past years. However, evidence of how to manage these findings is currently lacking. In this review, we summarize the current state of clonal hematopoiesis research and outline the challenges of developing clinical trials in this field. We anticipate that incidental findings of clonal hematopoiesis will become more common in the near future and argue that there is urgency to start designing and conducting prospective trials.
在过去的几年中，我们对克隆性造血与多种健康状况的关系的了解有了极大的增长，涉及到癌症医学以外的许多专业领域。鉴于克隆性造血在许多情况下可能是显性疾病的前兆，早期干预的前景引起了广泛关注。在这篇综述中，我们讨论了克隆性造血研究的现状，并概述了开发早期干预临床试验的挑战。我们预计，在不久的将来，克隆性造血的偶然发现将变得更加普遍，但目前缺乏有关如何处理这些发现的循证努力。
在过去的几年中，我们对克隆性造血相关性的了解有了巨大的增长。然而，目前尚缺乏有关如何处理这些发现的证据。在这篇综述中，我们总结了克隆性造血研究的现状，并概述了在该领域开展临床试验的挑战。我们预计，在不久的将来，克隆性造血的偶然发现将变得更加普遍，因此迫切需要开始设计和进行前瞻性试验。
